CN100569235C - 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 - Google Patents

用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 Download PDF

Info

Publication number
CN100569235C
CN100569235C CNB200580004060XA CN200580004060A CN100569235C CN 100569235 C CN100569235 C CN 100569235C CN B200580004060X A CNB200580004060X A CN B200580004060XA CN 200580004060 A CN200580004060 A CN 200580004060A CN 100569235 C CN100569235 C CN 100569235C
Authority
CN
China
Prior art keywords
pharmaceutical composition
physiology
asthma
acceptable salt
glycopyrronium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200580004060XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1913883A (zh
Inventor
J·格德
J·毛斯
P·J·克诺塔
I·塞莱尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Publication of CN1913883A publication Critical patent/CN1913883A/zh
Application granted granted Critical
Publication of CN100569235C publication Critical patent/CN100569235C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB200580004060XA 2004-02-06 2005-01-24 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 Expired - Fee Related CN100569235C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
US60/541,956 2004-02-06

Publications (2)

Publication Number Publication Date
CN1913883A CN1913883A (zh) 2007-02-14
CN100569235C true CN100569235C (zh) 2009-12-16

Family

ID=34837533

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200580004060XA Expired - Fee Related CN100569235C (zh) 2004-02-06 2005-01-24 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合

Country Status (16)

Country Link
US (2) US20050175548A1 (https=)
EP (1) EP1713473B1 (https=)
JP (1) JP4819699B2 (https=)
CN (1) CN100569235C (https=)
AU (1) AU2005210085B2 (https=)
CA (1) CA2551780C (https=)
DK (1) DK1713473T3 (https=)
ES (1) ES2413011T3 (https=)
HR (1) HRP20130460T1 (https=)
NO (1) NO336882B1 (https=)
NZ (1) NZ548300A (https=)
PL (1) PL1713473T3 (https=)
PT (1) PT1713473E (https=)
RU (1) RU2440813C2 (https=)
SI (1) SI1713473T1 (https=)
WO (1) WO2005074918A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
UA113832C2 (xx) 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
EP2515853B1 (en) 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
MX356386B (es) * 2012-08-09 2018-05-28 Chase Pharmaceuticals Corp Sales cuaternarias de piperidinio.
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP3473615B1 (en) 2013-02-28 2022-01-19 Journey Medical Corporation Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
EP3384898A1 (en) 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
MX387723B (es) 2016-09-19 2025-03-18 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения
JP7575099B2 (ja) 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
CN120360953B (zh) * 2025-06-24 2025-09-05 成都第一制药有限公司 一种用于copd治疗的莨菪烷类生物碱组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315852A (zh) * 1998-08-04 2001-10-03 杰格研究股份公司 药用气溶胶制剂
CN1326341A (zh) * 1998-11-13 2001-12-12 杰格研究股份公司 用于吸入给药的干粉
CN1422154A (zh) * 2000-04-07 2003-06-04 阿拉凯斯有限公司 呼吸系统疾病的治疗
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
WO2003086399A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittel enthaltend steroide und ein neues anticholinergikum

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
WO1999062720A1 (fr) * 1998-05-29 1999-12-09 Citizen Watch Co., Ltd. Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US6203779B1 (en) * 1999-03-19 2001-03-20 Charlie Ricci Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002096423A2 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
BR0209992A (pt) 2001-05-25 2004-04-06 Pfizer Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1487411B1 (en) * 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalable sustained therapeutic formulations
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
WO2004084897A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
DK1610787T3 (da) * 2003-03-28 2008-06-02 Nycomed Gmbh Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
JP2007530917A (ja) * 2003-07-11 2007-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 改善された周波数決定
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
WO2005082413A2 (en) 2004-02-27 2005-09-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315852A (zh) * 1998-08-04 2001-10-03 杰格研究股份公司 药用气溶胶制剂
CN1326341A (zh) * 1998-11-13 2001-12-12 杰格研究股份公司 用于吸入给药的干粉
CN1422154A (zh) * 2000-04-07 2003-06-04 阿拉凯斯有限公司 呼吸系统疾病的治疗
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
WO2003086399A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittel enthaltend steroide und ein neues anticholinergikum

Also Published As

Publication number Publication date
EP1713473A1 (en) 2006-10-25
RU2440813C2 (ru) 2012-01-27
DK1713473T3 (da) 2013-06-17
HRP20130460T1 (hr) 2013-06-30
US20080300226A1 (en) 2008-12-04
AU2005210085A1 (en) 2005-08-18
ES2413011T3 (es) 2013-07-15
CA2551780C (en) 2013-02-26
SI1713473T1 (sl) 2013-06-28
EP1713473B1 (en) 2013-03-13
CA2551780A1 (en) 2005-08-18
JP4819699B2 (ja) 2011-11-24
US10537550B2 (en) 2020-01-21
WO2005074918A1 (en) 2005-08-18
PL1713473T3 (pl) 2013-08-30
PT1713473E (pt) 2013-05-13
NO20063879L (no) 2006-11-01
JP2007520508A (ja) 2007-07-26
CN1913883A (zh) 2007-02-14
AU2005210085B2 (en) 2010-06-24
RU2006132038A (ru) 2008-03-20
HK1098356A1 (zh) 2007-07-20
NO336882B1 (no) 2015-11-23
US20050175548A1 (en) 2005-08-11
NZ548300A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
CN100569235C (zh) 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
CN101321539B (zh) 用于治疗炎性疾病的抗胆碱能药、糖皮质激素、β2-激动剂、PDE4抑制剂和抗白细胞三烯药的组合
RU2011133322A (ru) Фармацевтическая композиция для ингаляции
WO2000009127A1 (en) Remedies for multiple sclerosis
CA2701404A1 (en) Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders
US20200155513A1 (en) Thromboxane Receptor Antagonists in AERD/Asthma
WO2009032955A1 (en) Dheas inhalation compositions
CN104758294A (zh) 用于copd、哮喘治疗的吸入药物组合物及其制备方法
Kabir et al. Different approaches in the treatment of obstructive pulmonary diseases
HK1098356B (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
MXPA06008938A (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
Bayoumi-Ali et al. Drugs That Act on the Respiratory Tract
Pizzichini et al. Current role of anticholinergic drugs in the treatment of asthma
Dodwell et al. Respiratory system: applied pharmacology
CN118043051A (zh) 用于治疗或预防抗宿主病的吡咯并六元杂芳物
HK40066392A (zh) Aerd/哮喘中的血栓烷受体拮抗剂
CN117180235A (zh) 一种无定型雷芬那辛吸入制剂
Saul et al. Respiratory system: applied pharmacology
Veeren Bronchial Smooth Muscle Agents
Basavaraj A Prospective, Randomised, Placebo Controlled, Double Blinded Comparative Study of Ramosetron Hydrochloride 0.3 mg and Dexamethasone 8mg Versus Ondansetron Hydrochloride 4mg and Dexamethasone 8mg in Prevention of Post Operative Nausea and Vomiting, in Patients Undergoing Gynaecological Surgeries Under Spinal Anaesthesia
Bz-agonists BZ-Agonists
EP3458156A1 (en) Materials and methods for treating chronic cough

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098356

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098356

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091216

Termination date: 20220124

CF01 Termination of patent right due to non-payment of annual fee